Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes

Expert Review of Clinical Pharmacology

Volumn 4, Issue 3, 2011, Pages 363-377

  Cronin Fenton, Deirdre P ^a   Lash, Timothy L ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

breast cancer; breast cancer recurrence; cytochrome P450 2D6; selective serotonin reuptake inhibitors; tamoxifen

Indexed keywords

4 HYDROXYNORTAMOXIFEN; AFIMOXIFENE; ANASTROZOLE; CITALOPRAM; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; ESTER; ESTROGEN RECEPTOR; FLUOXETINE; FLUVOXAMINE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; NORTAMOXIFEN; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TAMOXIFEN; TAMOXIFEN GLUCURONIDE; TAMOXIFEN SULFATE ESTER; UNCLASSIFIED DRUG; VENLAFAXINE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DEPRESSION; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYDROXYLATION; DRUG INDUCED CANCER; DRUG METABOLISM; DRUG RESPONSE; ENDOMETRIUM CANCER; ENZYME INHIBITION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HERITABILITY; HETEROZYGOTE; HOMOZYGOTE; HOT FLUSH; HUMAN; META ANALYSIS; METABOLIC ACTIVATION; RECURRENCE RISK; REVIEW; TREATMENT OUTCOME; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; ENZYME INHIBITORS; FEMALE; HUMANS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 79955979258     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.11.18     Document Type: Review

References (104)

1. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472), 1687-1717 (2005).
2. Burstein HJ, Prestrud AA, Seidenfeld J et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J. Clin. Oncol. 28(23), 3784-3796 (2010).
3. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol. 20(8), 1319-1329 (2009).
4. Pirmohamed M. Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles. Clin. Pharmacol. Ther. 88(6), 862-866 (2010).
5. Wolf DM, Gottardis MM, Jordan VC. Tamoxifen-resistant growth. In:Long-Term Tamoxifen Treatment for Breast Cancer. Jordan VC (Ed.).University of Wisconsin Press, WI, USA, 181-198 (1994).
6. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9(9), 631-643 (2009).
7. Henriksen KL, Sonne-Hansen K, Kirkegaard T et al. Development of new predictive markers for endocrine therapy and resistance in breast cancer. Acta Oncol. 47(4), 795-801 (2008). (Pubitemid 351878456)
8. Lash TL, Lien EA, Sorensen HT et al. Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol. 10(8), 825-833 (2009).
9. Briest S, Stearns V. Tamoxifen metabolism and its effect on endocrine treatment of breast cancer. Clin. Adv. Hematol. Oncol. 7(3), 185-192 (2009).
10. Desta Z, Ward BA, Soukhova NV et al. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 310(3), 1062-1075 (2004). (Pubitemid 39108928)
11. Lim YC, Desta Z, Flockhart DA et al. Endoxifen (4-hydroxy-N-desmethyl- tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxytamoxifen. Cancer Chemother. Pharmacol. 55(5), 471-478 (2005). (Pubitemid 40568978)
12. Coezy E, Borgna JL, Rochefort H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res. 42(1), 317-323 (1982). (Pubitemid 12207285)
13. Lazarus P, Blevins-Primeau AS, Zheng Y et al. Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen. Ann. NY Acad. Sci. 1155, 99-111 (2009).
14. Gjerde J, Hauglid M, Breilid H et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann. Oncol. 19(1), 56-61 (2008).
15. Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst. 97(1), 30-39 (2005).
16. Blevins-Primeau AS, Sun D, Chen G et al. Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 69(5), 1892-1900 (2009).
17. Xu Y, Sun Y, Yao L et al. Association between CYP2D6 . z.ast;10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann. Oncol. 19(8), 1423-1429 (2008).
18. Jordan VC, Collins MM, Rowsby L et al. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol. 75(2), 305-316 (1977). (Pubitemid 8219148)
19. Lien EA, Solheim E, Kvinnsland S et al. Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res. 48(8), 2304-2308 (1988).
20. Adam HK, Douglas EJ, Kemp JV. The metabolism of tamoxifen in human. Biochem. Pharmacol. 28(1), 145-147 (1979).
21. Crewe HK, Ellis SW, Lennard MS et al. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol. 53(2), 171-178 (1997). (Pubitemid 27013472)
22. Li L, Borges S, Jason RD et al. A penalized mixture model approach in genotype/ phenotype association analysis for quantitative phenotypes. Cancer Inform. 9, 993-103 (2010).
23. Stearns V, Johnson MD, Rae JM et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl Cancer Inst. 95(23), 1758-1764 (2003). (Pubitemid 38008898)
24. Coller JK, Krebsfaenger N, Klein K et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4- hydroxytamoxifen in human liver. Br. J. Clin. Pharmacol. 54(2), 157-167 (2002). (Pubitemid 35024939)
25. Gallicchio L, Tkaczuk K, Lord G et al. Medication use, tamoxifen (TAM), and TAM metabolite concentrations in women with breast cancer. Cancer Lett. 211(1), 57-67 (2004). (Pubitemid 38759769)
26. Jordan VC. Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res. Treat. 2(2), 123-138 (1982). (Pubitemid 13233530)
27. Biglia N, Torta R, Roagna R et al. Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors. Maturitas 52(1), 78-85 (2005). (Pubitemid 41242746)
28. Henry NL, Rae JM, Li L et al. Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res. Treat. 117(3), 571-575 (2009).
29. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J. Clin. Oncol. 19(2), 322-328 (2001). (Pubitemid 32112842)
30. Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359(9324), 2131-2139 (2002). (Pubitemid 34694019)
31. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst. 97(22), 1652-1662 (2005). (Pubitemid 41672231)
32. Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer 101(3), 439-449 (2004). (Pubitemid 38970595)
33. Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. J. Clin. Oncol. 24(33), 5305-5312 (2006). (Pubitemid 46631378)
34. Swerdlow AJ, Jones ME. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J. Natl Cancer Inst. 97(5), 375-384 (2005). (Pubitemid 40425956)
35. Crewe HK, Lennard MS, Tucker GT et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br. J. Clin. Pharmacol. 34(3), 262-265 (1992).
36. Jeppesen U, Gram LF, Vistisen K et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur. J. Clin. Pharmacol. 51(1), 73-78 (1996). (Pubitemid 26300937)
37. Cronin-Fenton D, Lash TL, Sorensen HT. Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality. Future Oncol. 6(6), 877-880 (2010).
38. Sideras K, Ingle JN, Ames MM et al. Coprescription of tamoxifen and medications that inhibit CYP2D6. J. Clin. Oncol. 28(16), 2768-2776 (2010)
39. Borges S, Desta Z, Li L et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 80(1), 61-74 (2006). (Pubitemid 43946844)
40. Borges S, Desta Z, Jin Y et al. Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J. Clin. Pharmacol. 50(4), 450-458 (2010).
41. Chubak J, Buist DS, Boudreau DM et al. Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res. Treat. 112(1), 123-132 (2008).
42. Ahern TP, Pedersen L, Cronin-Fenton DP et al. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol. Biomarkers Prev. 18(9), 2562-2564 (2009).
43. Dezentje VO, van Blijderveen NJ, Gelderblom H et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J. Clin. Oncol. 28(14), 2423-2429 (2010).
44. Goetz MP, Knox SK, Suman VJ et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101(1), 113-121 (2007). (Pubitemid 47555336)
45. Kelly CM, Juurlink DN, Gomes T et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340, c693 (2010).
46. Lash TL, Pedersen L, Cronin-Fenton D et al. Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br. J. Cancer 99(4), 616-621 (2008).
47. Lash TL, Cronin-Fenton D, Ahern TP et al. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol. 49(3), 305-312 (2010).
48. Azoulay L, Dell'aniello S, Huiart L et al. Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence. Breast Cancer Res. Treat. (2010).
49. Siegelmann-Danieli N, Kurnik D, Lomnicky Y et al. Potent CYP2D6 inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res. Treat. 125(2), 505-510 (2011).
50. Lehmann D, Nelsen J, Ramanath V et al. Lack of attenuation in the anti-tumor effect of tamoxifen by chronic CYP isoform inhibition. J. Clin. Pharmacol. 44(8), 861-865 (2004). (Pubitemid 38971567)
51. Aubert RE, Stanek EJ, Yao J et al. Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. J. Clin. Oncol. 27 (2009) (Abstract 18S).
52. Bijl MJ, van Schaik RH, Lammers LA et al. The CYP2D6. *4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res. Treat. 118(1), 125-130 (2009).
53. Kiyotani K, Mushiroda T, Imamura CK et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J. Clin. Oncol. 28(8), 1287-1293 (2010).
54. Kiyotani K, Mushiroda T, Sasa M et al. Impact of CYP2D6. *10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 99(5), 995-999 (2008). (Pubitemid 351997603)
55. Newman WG, Hadfield KD, Latif A et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin. Cancer Res. 14(18), 5913-5918 (2008).
56. Nowell SA, Ahn J, Rae JM et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res. Treat. 91(3), 249-258 (2005). (Pubitemid 40903087)
57. Okishiro M, Taguchi T, Jin KS et al. Genetic polymorphisms of CYP2D6.10 and CYP2C19.2,.3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer 115(5), 952-961 (2009).
58. Ramon y Cajal T, Altes A, Pare L et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res. Treat. 119(1), 33-38 (2010).
59. Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 25(33), 5187-5193 (2007). (Pubitemid 350232249)
60. Schroth W, Goetz MP, Hamann U et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302(13), 1429-1436 (2009).
61. Toyama T, Yamashita H, Sugiura H et al. No association between CYP2D6.*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment. Jpn. J. Clin. Oncol. 39(10), 651-656 (2009).
62. Wegman P, Elingarami S, Carstensen J et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res. 9(1), R7 (2007).
63. Wegman P, Vainikka L, Stal O et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 7(3), R284-R290 (2005).
64. Leyland-Jones B, Regan MM, Bouzyk M et al. Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial. Presented at: San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-12 December 2010 (Abstract S1-8).
65. Rae JM, Drury S, Hayes DF et al. Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial. Presented at: San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-12 December 2010 (Abstract S1-7).
66. Oesterreich S, Hilsenbeck SH, Skaar T et al. Correlations between genetic variants in CYP2D6 and UGT2B7 and survival in breast cancer patients treated with or without tamoxifen: results from a large cohort study. Presented at: San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-12 December 2010 (Abstract P04-02-01).
67. Gor PP, Su HI, Gray RJ et al. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res. 12(3), R26 (2010).
68. Lash TL, Cronin-Fenton D, Ahern TP et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J. Natl Cancer Inst. 103(6), 489-500 (2011).
69. Abraham JE, Maranian MJ, Driver KE et al. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res. 12(4), R64 (2010).
70. Thompson AM, Johnson A, Quinlan P et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res. Treat. 125(1), 279-287 (2011).
71. Stingl JC, Parmar S, Huber-Wechselberger A et al. Impact of CYP2D6. *4 genotype on progression free survival in tamoxifen breast cancer treatment. Curr. Med. Res. Opin. 26(11), 2535-2542 (2010).
72. Schroth W, Hamann U, Fasching PA et al. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin. Cancer Res. 16(17), 4468-4477 (2010).
73. Kim H, Shin HC, Yom CK et al. Lack of significant association between CYP2D6 polymorphisms and clinical outcomes of adjuvant tamoxifen therapy. Presented at: San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-12 December 2010 (Abstract PD05-08).
74. Lash TL. Association between CYP2D6 polymorphisms and breast cancer outcomes. JAMA 303(6), 516 (2010).
75. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365(9453), 60-62 (2005).
76. Cuzick J, Sestak I, Baum M et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 11(12), 1135-1141 (2010).
77. Greenland S, Robins JM. Identifiability, exchangeability, and epidemiological confounding. Int. J. Epidemiol. 15(3), 413-419 (1986).
78. Myrand S, Sekiguchi K, Man M et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin. Pharmacol. Ther. 84(3), 347-361 (2008).
79. Rothman KJ, Greenland S, Lash TL. Types of epidemiologic studies. In:Modern Epidemiology (3rd Edition). Rothman KJ, Greenland S, Lash TL (Eds).Lippincott Williams & Wilkins, PA, USA, 95-97 (2008).
80. Rebsamen MC, Desmeules J, Daali Y et al. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J. 9(1), 34-41 (2009).
81. Owusu C, Buist DS, Field TS et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J. Clin. Oncol. 26(4), 549-555 (2008). (Pubitemid 351264347)
82. Geiger AM, Thwin SS, Lash TL et al. Recurrences and second primary breast cancers in older women with initial early-stage disease. Cancer 109(5), 966-974 (2007). (Pubitemid 46333538)
83. Rae JM, Sikora MJ, Henry NL et al. Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J. 9(4), 258-264 (2009).
84. Cole SR, Hernan MA. Fallibility in estimating direct effects. Int. J. Epidemiol. 31(1), 163-165 (2002). (Pubitemid 34284920)
85. Glymour M, Greenland S. Causal diagrams. In:Modern Epidemiology (3rd Edition).Rothman KJ, Greenland S, Lash TL (Eds).Lippincott Williams & Wilkins, PA, USA, 183-212 (2008).
86. Henry NL, Hayes DF, Rae JM. CYP2D6 testing for breast cancer patients: is there more to the story? Oncology (Williston Park).23(14), 1236, 1243, 1249 (2009).
87. Dunn BK, Greene MH, Kelley JM et al. Novel pathway analysis of genomic polymorphism-cancer risk interaction in the breast cancer prevention trial. Int. J. Mol. Epidemiol. Genet. 1(4), 332-349 (2010).
88. Gjerde J, Geisler J, Lundgren S et al. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer 10, 313 (2010).
89. Coller JK, Krebsfaenger N, Klein K et al. Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity. Br. J. Clin. Pharmacol. 57(1), 105-111 (2004). (Pubitemid 38067957)
90. Li-Wan-Po A, Girard T, Farndon P et al. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19. *17. Br. J. Clin. Pharmacol. 69(3), 222-230 (2010).
91. Ruiter R, Bijl MJ, van Schaik RH et al. CYP2C19.2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. Pharmacogenomics 11(10), 1367-1375 (2010).
92. Keshava C, McCanlies EC, Weston A. CYP3A4 polymorphisms - potential risk factors for breast and prostate cancer: a HuGE review. Am. J. Epidemiol. 160(9), 825-841 (2004). (Pubitemid 39434767)
93. Goetz MP, Rae JM, Suman VJ et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23(36), 9312-9318 (2005).
94. Falany CN, Wheeler J, Oh TS et al. Steroid sulfation by expressed human cytosolic sulfotransferases. J. Steroid Biochem. Mol. Biol. 48(4), 369-375 (1994). (Pubitemid 24128602)
95. Glatt H, Boeing H, Engelke CE et al. Human cytosolic sulphotransferases: genetics, characteristics, toxicological aspects. Mutat. Res. 482(1-2), 27-40 (2001). (Pubitemid 32787079)
96. Tabrett CA, Coughtrie MW. Phenol sulfotransferase 1A1 activity in human liver: kinetic properties, interindividual variation and re-evaluation of the suitability of 4-nitrophenol as a probe substrate. Biochem. Pharmacol. 66(11), 2089-2097 (2003). (Pubitemid 37377854)
97. Coughtrie MW, Gilissen RA, Shek B et al. Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations. Biochem. J. 337(Pt 1), 45-49 (1999). (Pubitemid 29039081)
98. Nowell S, Ambrosone CB, Ozawa S et al. Relationship of phenol sulfotransferase activity (SULT1A1) genotype to sulfotransferase phenotype in platelet cytosol. Pharmacogenetics 10(9), 789-797 (2000). (Pubitemid 32042831)
99. Raftogianis RB, Wood TC, Otterness DM et al. Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem. Biophys. Res. Commun. 239(1), 298-304 (1997). (Pubitemid 27480360)
100. McCarroll SA, Hadnott TN, Perry GH et al. Common deletion polymorphisms in the human genome. Nat. Genet. 38(1), 86-92 (2006). (Pubitemid 43011887)
101. Levesque E, Beaulieu M, Green MD et al. Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 7(4), 317-325 (1997). (Pubitemid 27356932)
102. Lash TL, Ahern TP, Cronin-Fenton D et al. Modification of tamoxifen response: what have we learned? J. Clin. Oncol. 26(10), 1764-1765 (2008).
103. Seruga B, Amir E. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Res. Treat. 122(3), 609-617 (2010).
104. Wu X, Subramaniam M, Grygo SB et al. Estrogen receptor-b sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Breast Cancer Res. 13(2), R27 (2011).